Effects of LX4211, a Dual Sodium-Dependent Glucose Cotransporters 1 and 2 Inhibitor, on Postprandial Glucose, Insulin, Glucagon-like Peptide 1, and Peptide Tyrosine Tyrosine in a Dose-Timing Study in Healthy Subjects

This clinical study indicates that dosing of LX4211 immediately before breakfast maximized the PD effects of both SGLT1 and SGLT 2 inhibition and provided a convenient dosing schedule for future trials. LX4211 was safe and well tolerated and, due to its SGLT1 inhibition, produced strong PPG reductions and low UGE relative to selective SGLT2 inhibitors. LX4211 may provide a promising new therapy for patients with type 2 diabetes mellitus. The potential long-term clinical benefits and safety of LX4211 treatment will need to be confirmed in large clinical trials. ClinicalTrials.gov identifier: NCT01334242.